Targets included in the Global Plan to Stop TB 2011–
2015 (2) stipulate that by 2015 all new cases of TB
considered at high risk of MDR-TB (about 20% of all
new confirmed cases), as well as all previously treated
cases, should receive DST for at least the first-line
drugs rifampicin and isoniazid, and that all patients with
confirmed MDR-TB should also be tested for XDR-TB.